A股異動 | 盤龍藥業(002864.SZ)漲逾6% 前三季度淨利同比增13.72%
格隆匯10月27日丨盤龍藥業(002864.SZ)高開高走,現報27.35元,漲幅6.21%,暫成交4737萬元,最新總市值23.7億。公司昨日公告稱,今年第三季度營業收入2.14億元,同比增長40.02%;歸屬於上市公司股東的淨利潤3357.3萬元,同比增長65.18%。前三季度營業收入4.51億,同比增3.55%;歸屬於上市公司股東的淨利潤6601.8萬元,同比增13.72%;經營活動產生的現金流量淨額3810.96萬元,同比增13.42%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.